Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.
- Mechanism
- Curator reviewed
MC-1 is a biologically active natural product which can be regarded as a chemical entity that has been evolutionarily selected and validated for binding to particular protein domains. Thus, its underlying structural architecture, or scaffold, has already been biologically established as safe and active, providing a powerful guiding principle for novel drug and library development.
- Primary indication
- Investigated for use/treatment in coronary artery disease.Curator reviewed
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with MC-1, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account